+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Neuralgia Treatment Market Research Report by Treatment Type, by Indication, by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 5146088
  • Report
  • September 2020
  • Region: Global
  • 150 pages
  • 360iResearch™
until Jun 30th 2021
The Global Neuralgia Treatment Market to Grow USD 1,301.31 Million by 2025, at a CAGR of 11.10%


  • Biogen Inc.
  • Cephalon Inc.
  • LGM Pharma LLC
  • Novartis AG
  • Teikoku Pharma USA, Inc.
The Global Neuralgia Treatment Market is expected to grow from USD 691.67 Million in 2019 to USD 1,301.31 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 11.10%.

Market Segmentation & Coverage:

This research report categorizes the Neuralgia Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Treatment Type, the Neuralgia Treatment Market is examined across Drug Based and Surgery. The Drug Based further studied across Anticonvulsant Medicines and Tricyclic Antidepressants. The Surgery further studied across Balloon Compression, Glycerol Injection, Microvascular Decompression, Radiofrequency Thermal Lesioning, and Stereotactic Radiosurgery.

Based on Indication, the Neuralgia Treatment Market is examined across Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, and Trigeminal Neuralgia.

Based on Distribution Channel, the Neuralgia Treatment Market is examined across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

The Asia-Pacific is projected to witness the highest growth during the forecast period

Based on Geography, the Neuralgia Treatment Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Neuralgia Treatment Market in 2019. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Neuralgia Treatment Market including Biogen Inc., Cadila Healthcare Limited, Cephalon Inc., GlaxoSmithKline PLC, GLENMARK PHARMS LTD., H. Lundbeck A/S, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., LGM Pharma LLC, Lupin Limited, Novartis AG, Pfizer Inc., Psychotropics India Limited, Takeda Pharmaceutical Company Limited, Teikoku Pharma USA, Inc., Teva Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and UCB Group.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neuralgia Treatment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. The ongoing research amplifies the research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Neuralgia Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neuralgia Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neuralgia Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Neuralgia Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Neuralgia Treatment Market?
6. What are the modes and strategic moves considered suitable for entering the Global Neuralgia Treatment Market?
Note: Product cover images may vary from those shown


  • Biogen Inc.
  • Cephalon Inc.
  • LGM Pharma LLC
  • Novartis AG
  • Teikoku Pharma USA, Inc.
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Indication Outlook
3.4. Distribution Channel Outlook
3.5. Treatment Type Outlook
3.6. Geography Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Increasing incidences of neuralgia due to the rise in the aging population
5.2.2. Government initiatives to spread awareness regarding neuralgia treatment products
5.3. Restraints
5.3.1. High-cost associated with the treatment of neuralgia
5.4. Opportunities
5.4.1. Technological advancement eliminates the need for drugs and surgery
5.4.2. Developing surgical and pharmacological treatment in developing economies
5.5. Challenges
5.5.1. Persistent side effects from medications

6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations
6.3.1. Regulatory Framework

7. Global Neuralgia Treatment Market, By Treatment Type
7.1. Introduction
7.2. Drug Based
7.2.1. Anticonvulsant Medicines
7.2.2. Tricyclic Antidepressants
7.3. Surgery
7.3.1. Balloon Compression
7.3.2. Glycerol Injection
7.3.3. Microvascular Decompression
7.3.4. Radiofrequency Thermal Lesioning
7.3.5. Stereotactic Radiosurgery

8. Global Neuralgia Treatment Market, By Indication
8.1. Introduction
8.2. Diabetic Neuropathy
8.3. Intercostal Neuralgia
8.4. Occipital Neuralgia
8.5. Peripheral Neuralgia
8.6. Postherpetic Neuralgia
8.7. Trigeminal Neuralgia

9. Global Neuralgia Treatment Market, By Distribution Channel
9.1. Introduction
9.2. Drug Stores
9.3. Hospital Pharmacies
9.4. Online Pharmacies
9.5. Retail Pharmacies

10. Americas Neuralgia Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Neuralgia Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. South Korea
11.10. Thailand

12. Europe, Middle East & Africa Neuralgia Treatment Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Biogen Inc.
14.2. Cadila Healthcare Limited
14.3. Cephalon Inc.
14.4. GlaxoSmithKline PLC
14.6. H. Lundbeck A/S
14.7. Janssen Pharmaceuticals, Inc.
14.8. Johnson & Johnson Services, Inc.
14.9. LGM Pharma LLC
14.10. Lupin Limited
14.11. Novartis AG
14.12. Pfizer Inc.
14.13. Psychotropics India Limited
14.14. Takeda Pharmaceutical Company Limited
14.15. Teikoku Pharma USA, Inc.
14.16. Teva Pharmaceuticals Ltd.
14.17. Torrent Pharmaceuticals Ltd.
14.18. UCB Group

15. Appendix
15.1. Discussion Guide
Note: Product cover images may vary from those shown
  • Biogen Inc.
  • Cadila Healthcare Limited
  • Cephalon Inc.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • LGM Pharma LLC
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Psychotropics India Limited
  • Takeda Pharmaceutical Company Limited
  • Teikoku Pharma USA, Inc.
  • Teva Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.
  • UCB Group
Note: Product cover images may vary from those shown